Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

UK Advisory Group Reverses Decision on Abiraterone; Drug Expected to Be Funded

May 18th 2012

The prostate cancer drug abiraterone acetate is expected be provided for patients through England's publicly funded healthcare system after NICE reversed its initial recommendation.

Dr. Goy on Neoadjuvant Hormonal Therapy Plus Zytiga

May 18th 2012

Dr. Andrew Goy, from John Theurer Cancer Center, on Neoadjuvant Hormonal Therapy Plus Zytiga

Neoadjuvant Zytiga Helps Eliminate Some Patients' Prostate Tumors

May 16th 2012

Combined neoadjuvant treatment with abiraterone acetate (Zytiga) plus standard hormonal therapy before prostatectomy eradicated or nearly eradicated tumors in 34% of patients with localized high-risk prostate cancer.

Dr. Gomella on Neoadjuvant Hormonal Therapy Plus Zytiga

May 16th 2012

Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, on Neoadjuvant Hormonal Therapy Combined With Abiraterone Acetate

New Therapies for Prostate Cancer: The Practicalities

May 15th 2012

Now, with four new agents approved in the last two years and two promising agents in the pipeline, therapy selection and potential outcomes are changing.

5-alpha Reductase Inhibitors Help Prostate Cancer Patients on Active Surveillance

May 14th 2012

Men with low-risk prostate cancer who have opted for active surveillance are about half as likely to experience pathologic progression or abandon active surveillance if they take a 5-ARI.

Sipuleucel-T Stimulates Response in Localized Setting, Study Finds

May 11th 2012

The neoadjuvant administration of sipuleucel-T may stimulate an immune response in patients with localized prostate cancer without adversely affecting their surgeries.

Dr. Dreicer on Utilizing New Prostate Cancer Therapies

May 9th 2012

Dr. Robert Dreicer, from the Cleveland Clinic, on Utilizing New Prostate Cancer Therapies

Dutasteride May Slow Prostate Cancer Progression

May 5th 2012

Dutasteride may postpone disease progression in men with low-risk prostate cancer who have opted for an active surveillance strategy.

Talking to Prostate Cancer Patients About Sipuleucel-T: Nurses Assure Smooth Sailing During Treatment

May 4th 2012

Nurses play vital roles in assuring that patients with metastatic castration-resistant prostate cancer (mCRPC) are optimally treated with sipuleucel-T.

Dr. Leonard Gomella Discusses PSA Velocity

May 1st 2012

Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, Discusses PSA Velocity

Coronary Artery Disease May Boost Risk of Prostate Cancer

April 30th 2012

Coronary artery disease and prostate cancer have been shown to share several modifiable and nonmodifiable risk factors including age, race, family history, and possibly diet.

Dr. Petrylak Discusses the Future of Abiraterone Acetate

April 27th 2012

Dr. Daniel Petrylak, from the Herbert Irving Comprehensive Cancer Center, Discusses the Future of Abiraterone Acetate

Dr. Sartor on Combining Radium-223 and Provenge

April 25th 2012

Dr. Oliver Sartor, from Tulane Cancer Center, Discusses a New Trial Combining Radium-223 and Provenge

Dr. Sandler Describes the RTOG 9408 Trial Results

April 23rd 2012

Dr. Howard Sandler, from Cedars-Sinai Medical Center, Describes the RTOG 9408 Prostate Cancer Trial Results

Dr. Gomella Suggests Provenge Benefit Understated

April 20th 2012

Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, Examines the Understating of Provenge Benefits

"Scotty, I Need More Power"

April 20th 2012

The paradigm of "more energy is better" is not limited to space travel, and in fact is center stage in a growing debate in the field of radiation oncology.

Revised View Enhances Provenge OS Data

April 19th 2012

A further analysis of clinical trial data for sipuleucel-T suggests that it may have delivered a greater OS benefit than previously described.

Dr. Dreicer on Sequencing MDV3100 and Abiraterone

April 18th 2012

Dr. Robert Dreicer, from the Cleveland Clinic, Discusses Sequencing MDV3100 and Abiraterone

April 2012: Trials in Progress

April 17th 2012

The Trials in Progress section supplies summaries of ongoing research in a broad range of cancer types.